Recent Updates
Recently added Catalysts

LY4560736

Phase 1

Alzheimer Disease | Small Molecules | Neurology |Eli Lilly and Company|Trials Updated: Nov 18, 2026

LY4560736 development status

Highest phase Phase 1
Registered trials 1 across 1 sponsor since Sep 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials1
Total Enrollment111

FDA Designations

No designations recorded

LY4560736 clinical trials

LY4560736 · 1 trial · 5 indications

Phase 1 1
NCT07843459A Study of LY4560736 in Healthy Participants and Participants With Alzheimer's Disease (AD)Healthy Volunteers
RECRUITING111 Analytics
PHASE1RECRUITING
A Study of LY4560736 in Healthy Participants and Participants With Alzheimer's Disease (AD)
Healthy VolunteersUnlock trial analytics

Study Endpoints

Primary Endpoints

Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Baseline up to 13 Weeks

Secondary Endpoints

Pharmacokinetics (PK): Area Under the Plasma Concentration-Time Curve from Time Zero to Infinity (AUC0-∞) Following a Single Dose of LY4560736 in Healthy Participants
Baseline, Week 5
PK: Plasma LY4560736 Maximum Concentration at Steady State (Cmax,ss) in Participants with AD
Baseline through Week 13
Concentration of LY4560736 in Cerebrospinal Fluid (CSF) in Healthy Participants
Baseline through Study Completion (13 Weeks)
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
LY4560736 Part A: Single-Ascending Dose (SAD)EXPERIMENTALLY4560736 administered intravenously (IV) or subcutaneously (SC) in healthy volunteers.
Placebo Part APLACEBO_COMPARATORPlacebo administered IV or SC in healthy volunteers.
LY4560736 Part B: Multiple Ascending Dose (MAD)EXPERIMENTALLY4560736 administered IV to participants with AD. Florbetapir F 18 or Florbetaben F 18 will be administered IV during amyloid positron emission tomography (PET) scan.
Placebo Part BPLACEBO_COMPARATORPlacebo administered IV to participants with AD. Florbetapir F 18 or Florbetaben F 18 will be administered IV during amyloid PET scan.

Interventions

NameTypeDescription
LY4560736DRUGAdministered intravenously (IV)
PlaceboDRUGAdministered IV
Florbetapir F18OTHERAdministered IV
Florbetaben F 18OTHERAdministered IV
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 85 Years
SexALL
Healthy VolunteersYes
Study Sites19

Inclusion Criteria: * Participants must meet eligibility criteria in the A1D-MC-ATMP screening protocol before entry into the treatment study. * To qualify as a participant of first-generation Japanese origin, the participant, the participant's biological parents, and all the participant's biologic...

Countries:United StatesChinaJapan
Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

LOWNov 18, 2026NCT07843459Status: NOT_YET_RECRUITING → RECRUITING
LOWNov 18, 2026NCT07843459Status: NOT_YET_RECRUITING → RECRUITING
LOWOct 8, 2026NCT07843459lastUpdatePostDate: changed
LOWOct 8, 2026NCT07843459lastUpdatePostDate: changed
LOWSep 28, 2026NCT07843459NEW_TRIAL: changed
LOWSep 28, 2026NCT07843459NEW_TRIAL: changed

Frequently asked questions about LY4560736

What is LY4560736?

LY4560736 is an investigational small molecule being developed by Eli Lilly and Company for Alzheimer disease. It is in Phase 1 clinical development and has not been approved by the FDA. It is being studied in healthy participants as well as participants with Alzheimer disease.

What is LY4560736 used for in Alzheimer disease?

LY4560736 is being studied as a potential treatment for Alzheimer disease. The Phase 1 program also enrolls healthy volunteers, and trial conditions include amyloid plaque and plasma amyloid measures. It is investigational, meaning it is not approved for any use and remains in clinical development.

Who makes LY4560736?

LY4560736 is being developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. Lilly is the sponsor of the Phase 1 study evaluating the compound in healthy participants and participants with Alzheimer disease.

What phase is LY4560736 in?

LY4560736 is in Phase 1 clinical development. One Phase 1 trial is registered and is currently active, with a status of not yet recruiting. No Phase 2 or Phase 3 studies have been registered, and the drug is not FDA approved.

What clinical trials is LY4560736 in?

LY4560736 is being evaluated in one registered Phase 1 trial, NCT07843459, titled A Study of LY4560736 in Healthy Participants and Participants With Alzheimer's Disease. The trial is randomized, double blind, and placebo controlled, plans to enroll 111 participants, and is being run in the United States, China, and Japan.